TITLE

PHARMACODYNAMICS OF PARENTERAL AND ORAL ANTICOAGULANTS

AUTHOR(S)
Fremont, Rudolph E.
PUB. DATE
March 1964
SOURCE
Angiology;Mar1964, Vol. 15 Issue 3, p152
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Discusses the potential clinical usefulness of heparin. Assessment of pharmacodynamics and biological activity of heparin; Capacity of heparin to reduce platelet adhesiveness by interfering with the layer of fibrin deposited on the surface of the platelets; Clinical efficacy of the drug in the treatment of acute myocardial infarction.
ACCESSION #
16371427

 

Related Articles

  • Effects of Nisoldipine on Cytosolic Calcium, Platelet Aggregation, and Coagulation/Fibrinolysis in Patients with Coronary Artery Disease. Fujinishi, Akiko; Takahara, Kazuo; Ohba, Chizuko; Nakashima, Yasuhide; Kuroiwa, Akio // Angiology;Jun1997, Vol. 48 Issue 6, p515 

    The effect of nisoldipine, a dihydropyridine Ca2+ antagonist, on the platelet cytosolic Ca2+ concentration ([Ca2+]i), platelet aggregation, and various coagulation and fibrinolysis parameters was assessed in normotensive patients with coronary artery disease (CAD). Eleven patients with...

  • Benefits and limitations of current antiplatelet therapies. Nappi, Jean // American Journal of Health-System Pharmacy;Jul2008 Supplement, Issue S5, pS5 

    Purpose. The benefits and limitations of current antiplatelet therapies in the management of patients experiencing acute coronary syndrome (ACS) are reviewed. Summary. Antiplatelet agents, including aspirin, thienopyridines, and platelet glycoprotein (GP) IIb/IIIa receptor inhibitors, have...

  • A COMPARISON STUDY TO DETECT PLATELET SENSITIVITY TO ASPIRIN BY PLATELET AGGREGATION METHODS. Sanada, A. B.; Zaidah, A. Wan; Rosline, H.; Zurkurnai, Y.; M. H., Tee; Suhairi, I.; R., Madhavan // Malaysian Journal of Medical Sciences;Jan2007 Supplement, Vol. 14, p174 

    Introduction: Aspirin or acetylsalicylic acid is an anti-platelet agent used to prevent thromboembolic complications related to cardiovascular diseases. Unfortunately aspirin's anti-platelet effect may not be uniform in all patients. The aim of this study is to detect platelet sensitivity to...

  • Lack of In Vitro Cross-Reactivity Predicts Safety of Low-Molecular Weight Heparins in Heparin-Induced Thrombocytopenia. Farag, Sherif S.; Savoia, Helen; O'Malley, Cindy J.; McGrath, Katherine M. // Clinical & Applied Thrombosis/Hemostasis;Jan1997, Vol. 3 Issue 1, p58 

    Alternative anticoagulation in patients with heparin-induced thrombocytopenia (HIT) is often problematic. The relatively high cross-reactivity rate reported for the low-molecular-weight heparins (LMWH) has discouraged their use in this setting. This study has investigated the safety of using the...

  • Circulating Platelet Aggregate Size in Ischemic Heart Disease. Weinberger, Itzhak; Fuchs, Jacob; Rotenberg, Zvi; Almozlino, Avi; Joshua, Henry; Agmon, Jacob // Angiology;Sep1986, Vol. 37 Issue 9, p676 

    Platelet aggregate size was measured in 178 patients with ischemic heart disease, among whom 56 had stable angina, 42 suffered from unstable angina, and 80 had had uncomplicated acute myocardial infarction. A group of 50 healthy volunteers and 20 hospitalized noncardiac patients served as...

  • The Antithrombotic Efficacy of Lotrafiban (SB 214857) in Canine Models of Acute Coronary Thrombosis. Toomey, J.R.; Samanen, J.; Valocik, R.E.; Koster, P.F.; Barone, F.C.; Willette, R.N. // Current Drug Targets - Cardiovascular & Haematological Disorders;Jun2002, Vol. 2 Issue 1, p13 

    In patients with acute coronary syndromes, inhibition of platelet aggregation with parenteral aIIb / �III antagonists has proven effective at preventing nonfatal myocardial infarction and repeat percutaneous coronary interventions. Paradoxically, the efficacy observed for acute indications...

  • Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission ot NICE, and beyond. Manoharan, G.; Adgey, A. A. J. // Heart;Sep2001, Vol. 86 Issue 3, p259 

    Acute coronary syndromes constitute a spectrum of clinical conditions and can be divided into non-ST segment elevation and ST segment elevation myocardial infarction. Hospital admissions for unstable angina are increasing and have now exceeded those for acute myocardial infarction, with the...

  • High Blood Glucose Is Cause for Concern, Even Among Non-Diabetics.  // Women's Nutrition Connection;Oct2012, Vol. 15 Issue 10, p1 

    The article focuses on study regarding high blood glucose which is a cause for concern among non-diabetics. It says that study reveals that high glucose levels in non-diabetics may increase the risk of ischemic heart disease (IHD) and myocardial infarction (MI). According to endocrinologist...

  • Abatacept: A Viewpoint by Paul Emery. Emery, Paul // BioDrugs;2006, Vol. 20 Issue 1, p62 

    Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway.Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics